PMID- 32547147
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 13
DP  - 2020
TI  - Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus.
PG  - 1855-1861
LID - 10.2147/DMSO.S253967 [doi]
AB  - Diabetes mellitus (DM) is a worldwide health threat affecting millions of people, 
      which is associated with different micro- and macro-vascular complications. Type 
      2 diabetes mellitus (T2DM) is one of the different types of DM caused by insulin 
      resistance and/or reduced secretion of insulin from the pancreas. A validated 
      novel biomarker is required to enhance the accuracy of disease prediction, 
      provide novel insights into pathophysiology and contribute to future prevention 
      of T2DM. Various newer diagnostic methods have been developed by targeting 
      endogenous proteins among which Adipsin is one of the promising target. 
      Therefore, this review discusses Adipsin as a potential biomarker and its 
      implication in T2DM. Adipsin is one of the adipokines secreted by adipose tissues 
      which is involved in maintaining adipose tissue homeostasis and increasing 
      insulin secretion in response to glucose. According to different experimental and 
      clinical studies, plasma Adipsin concentrations are low in animals and patients 
      with DM which support its use as a biomarker in combination to the other 
      diagnostic modalities for DM. Additionally, the existence of Adipsin could be 
      important in improving hyperglycemia by preserving beta-cell mass through improving 
      beta-cell survival and maintaining their transcriptional identity.
CI  - (c) 2020 Tafere et al.
FAU - Tafere, Gebrehiwot Gebremedhin
AU  - Tafere GG
AUID- ORCID: 0000-0002-6274-0106
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle 
      University, Mekelle, Ethiopia.
FAU - Wondafrash, Dawit Zewdu
AU  - Wondafrash DZ
AUID- ORCID: 0000-0003-1127-6443
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle 
      University, Mekelle, Ethiopia.
FAU - Zewdie, Kaleab Alemayehu
AU  - Zewdie KA
AUID- ORCID: 0000-0002-7089-421X
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle 
      University, Mekelle, Ethiopia.
FAU - Assefa, Brhane Teklebrhan
AU  - Assefa BT
AUID- ORCID: 0000-0002-6182-6549
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle 
      University, Mekelle, Ethiopia.
FAU - Ayza, Muluken Altaye
AU  - Ayza MA
AUID- ORCID: 0000-0001-6196-0361
AD  - Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle 
      University, Mekelle, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200528
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC7264027
OTO - NOTNLM
OT  - adipsin
OT  - biomarker
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
PMCR- 2020/05/28
CRDT- 2020/06/18 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
PHST- 2020/05/28 00:00 [pmc-release]
AID - 253967 [pii]
AID - 10.2147/DMSO.S253967 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2020 May 28;13:1855-1861. doi: 10.2147/DMSO.S253967. 
      eCollection 2020.